AstraZeneca to Spend $190M for New UK Facility

Nov 11, 2013

World Pharma News

AstraZeneca announced plans to invest $190 million in a new facility at its global manufacturing site in Macclesfield, UK, to continue production of Zoladex, an injectable treatment for patients with prostate cancer. The investment secures 300 existing Zoladex jobs at the site and will create more than 200 temporary jobs during the construction and commissioning phase between now and early 2017. Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments